Welcome to our dedicated page for Radius Recycling news (Ticker: RDUS), a resource for investors and traders seeking the latest updates and insights on Radius Recycling stock.
Radius Recycling, Inc. (NASDAQ: RDUS), formerly known as Schnitzer Steel Industries, Inc., stands as a prominent figure in North America's recycling and steel manufacturing industry. Established in 1906 in Portland, Oregon, the company has evolved from a small, one-man scrap metal operation into a major player in the market, boasting a diversified and vertically integrated business model.
Radius Recycling specializes in the recycling of ferrous and nonferrous metals, including end-of-life vehicles, and the manufacture of finished steel products. Their operational network comprises 54 metals recycling facilities, 50 self-service auto parts stores, and an electric arc furnace steel mill. This extensive infrastructure enables Radius to meet global demand efficiently.
Key Business Units:
- Metals Recycling Business: Processes a substantial quantity of recycled ferrous and nonferrous metals, significantly contributing to environmental sustainability and resource conservation.
- Auto Parts Business: Operates 50 retail stores selling serviceable parts from salvaged vehicles, receiving over 4 million annual visits from retail customers.
- Steel Manufacturing Business: Produces a variety of finished steel products, including rebar and wire rod, using eco-friendly electric arc furnace technology.
Despite the challenges posed by tight supply flows and adverse weather conditions impacting sales volumes, Radius Recycling has demonstrated resilience and adaptability. Recent productivity initiatives aim to reduce selling, general, and administrative expenses by 10%, alongside increasing production efficiencies, expected to yield $40 million in annual benefits.
Recent Financial Highlights:
- Revenue: Achieved $2.5 billion in fiscal 2014, reflecting robust market presence and operational efficiency.
- Global Reach: Positions in 25 states, Puerto Rico, and Western Canada, with deep-water export facilities expanding its market access.
- Strategic Initiatives: Focused on enhancing nonferrous production and expanding recycling services, positioning the company favorably against market headwinds.
Under the leadership of Tamara Lundgren, Chairman and CEO, Radius Recycling remains focused on cost control, operational efficiency, and strategic growth. The company's commitment to sustainability and low-carbon technologies aligns with global decarbonization trends, positioning Radius to capitalize on future market opportunities.
Partnerships and Projects: Radius continues to invest in advanced metal recovery technologies and expand its recycling platform, supporting its mission of promoting environmental sustainability and efficient resource use.
The company will report its financial results for the second quarter of fiscal 2024 on April 4, 2024, with a webcast conference call hosted by Tamara Lundgren and Stefano Gaggini, Senior Vice President and CFO, to discuss the results.
Radius Health will host a webcast on April 5, 2022, from 10:00 AM to 12:00 PM ET to discuss RAD011, an investigational synthetic cannabidiol oral solution. The webinar aims to provide insights on the asset's overview, scientific data, regulatory status, and clinical progress since acquisition. Key topics include its therapeutic potential for neuro-endocrine and neurodevelopmental conditions, including Prader-Willi and Angelman syndromes. The event will feature presentations by various experts and a Q&A session for investors and analysts.
Radius Health, Inc. (Nasdaq: RDUS) has appointed Mark Conley as Chief Financial Officer and promoted Kim Clarke to General Counsel as of March 16, 2022. Conley, with over 30 years of experience in finance, previously held roles at Kaleido Biosciences and Thermo Fisher Scientific. Clarke, who joined Radius in 2021, has a background in regulatory affairs from her time at GlaxoSmithKline. Both will report to CEO Kelly Martin and are expected to enhance Radius's leadership as it progresses in addressing medical needs in bone health, orphan diseases, and oncology.
Radius Health, Inc. (NASDAQ: RDUS) has extended its research collaboration with Massachusetts General Hospital to develop novel oral SIK inhibitors for musculoskeletal diseases, building on successful nonclinical data. The collaboration aims to progress a candidate molecule for treating disorders like osteoporosis. Additionally, a new patent for TYMLOS® has been issued, extending its exclusivity until January 10, 2040. This strengthens Radius' intellectual property and supports future developments in therapies for osteoporosis and related conditions.
BOSTON, March 07, 2022 – Radius Health, Inc. (NASDAQ: RDUS) announced that CEO Kelly Martin will join a virtual fireside chat hosted by Wells Fargo's Mohit Bansal on March 11, 2022, at 11:00am ET. The event will be accessible via a live webcast on the company's investor relations website.
Radius is a biopharmaceutical company focused on bone health, orphan diseases, and oncology, with its lead product, TYMLOS® (abaloparatide), approved for treating postmenopausal women at high risk for osteoporosis-related fractures.
Radius Health announced a virtual R&D Webcast on April 5, 2022, focusing on RAD011, its investigational synthetic cannabidiol oral solution. RAD011 targets multiple orphan diseases, including Prader-Willi syndrome, Angelman syndrome, and infantile spasms. The webcast will discuss the asset's history, rationale for different indications, and competitive landscape. The event starts at 10:00 AM EST and will include a 30-minute Q&A. Interested parties can access the call via a provided link or dial-in numbers. A replay will be available later on the company's website.
Radius Health filed a Supplemental New Drug Application (sNDA) with the FDA on February 25, 2022, ahead of schedule. This filing is based on positive results from the Phase 3 ATOM study, which demonstrated significant increases in bone mineral density (BMD) in men with osteoporosis. The FDA's review period is expected to last 10 months. The full dataset from the ATOM study will be presented at the AACE Annual Meeting on May 12-14, 2022. This marks a crucial step for Radius in making TYMLOS available for the treatment of osteoporosis in men.
Radius Health reported Q4 2021 net revenue of $65 million, a 9% increase from Q4 2020. Full-year revenue for TYMLOS was $219 million, up 5% year-over-year. The company achieved a 36% reduction in net loss, totaling ($70 million) for FY 2021, and a 56% improvement in adjusted EBITDA loss of ($24 million).
2022 objectives include projected TYMLOS revenue of $232 million and continued focus on pivotal trials for RAD011. CEO Kelly Martin emphasized a pivotal year for the company with plans for capital returns and enhanced operational effectiveness.
Radius Health, Inc. (NASDAQ: RDUS) will release its fourth quarter and full year 2021 financial results on February 24, 2022. Following the announcement, the company will host a conference call at 8:30 a.m. ET to discuss results and provide updates. Interested parties can join via dial-in or webcast. A replay of the call will be available starting on February 24 at 11:30 a.m. ET through March 3. Radius Health focuses on biopharmaceuticals in bone health, neuroscience, and oncology.
Radius Health, Inc. (NASDAQ: RDUS) has restructured its operations following the completion of three pivotal clinical trials in 2021. The restructuring entailed a reduction of approximately 20% in non-sales headcount, targeting roles supporting the abaloparatide clinical and regulatory activities. While the ATOM and EMERALD studies reported positive outcomes, the wearABLe study failed to meet its primary endpoint. The company is set to report its Q4 and FY 2021 results along with its 2022 outlook on February 24, 2022.
Radius Health announced that the FDA has approved the removal of the boxed warning regarding osteosarcoma risks from the label of TYMLOS, effective December 22, 2021. This decision follows a comprehensive review of long-term post-marketing data. The update aims to provide healthcare professionals and patients with critical information for better treatment decisions. Radius remains focused on exploring further label adjustments with ongoing discussions with the FDA.
FAQ
What is the current stock price of Radius Recycling (RDUS)?
What is the market cap of Radius Recycling (RDUS)?
What is Radius Recycling, Inc.?
What does Radius Recycling do?
Where is Radius Recycling headquartered?
What are the key business units of Radius Recycling?
How has Radius Recycling performed financially?
What are the latest financial results for Radius Recycling?
What are Radius Recycling's strategic initiatives?
Who is the CEO of Radius Recycling?
How does Radius Recycling contribute to sustainability?
Where can I find more information about Radius Recycling?
